Differentiated Pediatric Thyroid Cancer: Correlates With Adult Disease, Controversies in Treatment

Seminars in Nuclear Medicine

Volumn 37, Issue 5, 2007, Pages 340-356

  Parisi, Marguerite T ^a,b   Mankoff, David ^b,c  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 123; IODINE 131; LIOTHYRONINE SODIUM; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PERTECHNETIC ACID TC 99M; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THALLIUM 201;

ABSENCE OF SIDE EFFECTS; ADULT DISEASE; AMENORRHEA; AZOOSPERMIA; BIRTH DEFECT; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CHILDHOOD CANCER; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; FOLLOW UP; GENETIC DISORDER; HUMAN; HYPERTHYROIDISM; INFERTILITY; INTESTINE CANCER; LEUKEMIA; LOBECTOMY; LUNG FIBROSIS; MENSTRUAL IRREGULARITY; METASTASIS; NAUSEA; OLIGOSPERMIA; OVARY INSUFFICIENCY; POSITRON EMISSION TOMOGRAPHY; PREGNANCY DISORDER; PROGNOSIS; RADIATION INJURY; RECOMMENDED DRUG DOSE; REVIEW; SALIVARY GLAND CANCER; SIALOADENITIS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; THYROID DISEASE; THYROIDECTOMY; TREATMENT RESPONSE; XEROSTOMIA;

ADULT; CHILD; HUMANS; INCIDENCE; PEDIATRICS; POSITRON-EMISSION TOMOGRAPHY; STATISTICS; THYROID NEOPLASMS;

EID: 34547838284     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2007.05.001     Document Type: Review

References (147)

1. Schlumberger M.J. Papillary and follicular thyroid carcinoma. N Engl J Med 338 (1998) 297-306
2. Ries LAG, Eisner MP, Kosary CL, et al: 2000 SEER Cancer Statistics Review, 1973-1977. Bethesda, MD, National Cancer Institute.
3. Pacini F. Thyroid cancer in children and adolescents. J Endocrinol Invest 25 (2002) 572-573
4. Kebebew E., Ituarte P.H.G., Siperstein A.E., et al. Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88 (2000) 1139-1148
5. Buckwalter J.A., Gurll N.J., and Thomas Jr. C.G. Cancer of the thyroid in youth. World J Surg 5 (1981) 15-25
6. Harach H.R., and Williams E.D. Childhood thyroid cancer in England and Wales. Br J Cancer 72 (1995) 777-783
7. DeKeyser L.F.M., and Van Herle A.J. Differentiated thyroid cancer in children. Head Neck Surg 8 (1985) 100-114
8. Winship T., and Rosvoll R.V. Childhood thyroid carcinoma. Cancer 14 (1961) 734-743
9. Ries LAG, Harkins D, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2003, National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2003/. Based on November 2005 SEER data submission, posted to the SEER web site, 2006
10. Bernstein L., and Gurney J.G. Carcinomas and other malignant epithelial neoplasms. ICCC XI. Pediatric Monograph. In: Ries L.A.G., Smith M.A., Gurney J.G., et al. (Eds). Cancer Incidence and Survival Among Children and Adolescents (1999), National Cancer Institute, Bethesda, MD United States SEER Program 1975-1995, SEER Program NIH Pub. No. 99-4649
11. Waguespack S., Wells S., Ross J., et al. Thyroid Cancer. SEER AYA Monograph. In: Bleyer A., O'Leary M., Barr R., et al. (Eds). Cancer Epidemiology in Older Adolescents and Young Adults 15-29 Years of Age, Including SEER Incidence and Survival: 1975-2000 (2006), National Cancer Institute, Bethesda, MD NIH Pub. NO. 06-5767
12. Crile G. Carcinoma of the thyroid in children. Ann Surg 150 (1959) 959-964
13. Duffy B.J., and Fitzgerald P.J. Cancer of the thyroid in children: A report of 28 cases. J Clin Endocrinol Metab 10 (1950) 1296-1308
14. LaQuaglia M.P., and Telander R.L. Differentiated and medullary thyroid cancer in childhood and adolescence. Semin Pediatr Surg 6 (1997) 42-49
15. Winship T., and Rosvall R.V. Thyroid carcinoma in childhood: Final report on a 20 year study. Clin Proc Children's Hosp Washington DC 26 (1970) 327-349
16. Schlumberger M., de Vathaire F., Travagli J.P., et al. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 65 (1987) 1088-1094
17. Ceccarelli C., Pacini F., Lippi F., et al. Thyroid cancer in children and adolescents. Surgery 104 (1988) 1143-1148
18. Zimmerman D., Hay I.D., Gough I.R., et al. Papillary thyroid carcinoma in children and adults: Long-term follow-up of 1039 patients conservatively treated at one institution over three decades. Surgery 104 (1988) 1157-1166
19. Samuel A.M., and Sharma S.M. Differentiated thyroid carcinomas in children and adolescents. Cancer 67 (1991) 2186-2190
20. McClellan D.R., and Francis G.L. Thyroid cancer in children, pregnant women and patients with Graves' disease. Endocrinol and Metab Clin North Am 25 (1996) 27-48
21. Dottorini M.E., Vignati A., Mazzucchelli L., et al. Differentiated thyroid carcinoma in children and adolescents: A 37 year experience in 85 patients. J Nucl Med 38 (1997) 669-675
22. Sykes A.J., and Gattamameni H.R. Carcinoma of the thyroid in children: A 25 year experience. Med Pediatr Oncol 29 (1997) 103-107
23. Landau D., Vini L., Hern R.A., et al. Thyroid cancer in children: The Royal Marsden Hospital experience. Eur J Cancer 36 (2000) 214-220
24. Ben Arush M.W., Stein M.E., Perez Nahum M., et al. Pediatric thyroid carcinoma: 22 years of experience at the Northern Israel Oncology Center (1973-1995). Pediatr Hematol Oncol 17 (2000) 85-92
25. Bauer A.J., Tuttle R.M., and Francis G.L. Differentiated thyroid carcinoma of children and adolescents. Endocrinologist 12 (2002) 135-142
26. Arici C., Erdogan O., Altunbas H., et al. Differentiated thyroid carcinoma in children and adolescents. Horm Res 57 (2002) 153-156
27. La Quaglia M.P., Corbally M.T., Heller G., et al. Recurrance and morbidity in differentiated thyroid cancer in children. Surgery 104 (1988) 1149-1156
28. Alessandri A.J., Goddard K.J., Blair G.K., et al. Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Med Pediatr Oncol 35 (2000) 41-46
29. Brink J.S., van Heerden J.A., McIver B., et al. Papillary thyroid cancer with pulmonary metastases in children: long term prognosis. Surgery 128 (2000) 881-887
30. Kowalski L.P., Fihlo J.G., Pinto C.A.L., et al. Long-term survival rates in young patients with thyroid carcinoma. Arch Otolaryngol Head Neck Surg 129 (2003) 746-749
31. Jhiang S.M., Fithian L., Weghorst C.M., et al. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma. Thyroid 6 (1996) 115-121
32. Pacini F., Elisei R., Romei C., et al. RET proto-oncogene mutations in thyroid carcinomas: Clinical relevance. J Endocrinol Invest 23 (2000) 328-338
33. Sadetzki S., Calderon-Margalit R., Modan B., et al. Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external beam irradiation in childhood. J Clin Endocrinol Metab 89 (2004) 2281-2289
34. Martins R.G., Rajendran J.G., Capell P., et al. Medullary thyroid cancer-options for systemic therapy of metastatic disease?. J Clin Oncol 24 (2006) 1653-1655
35. Clark D.E. Association of irradiation with cancer of the thyroid in children and adolescents. JAMA 159 (1955) 1007-1009
36. Parker L.N., Belsky J.L., Yamamoto T., et al. Thyroid carcinoma after exposure to atomic radiation: a continuing survey of a fixed population Hiroshima and Nagasaki, 1958-1971. Ann Intern Med 80 (1974) 600-604
37. Johnson C.J. Cancer incidence in an area of radioactive fallout downwind from the Nevada test site. JAMA 251 (1984) 230-236
38. Hamilton T.E., van Belle G., and LoGerfo J.P. Thyroid neoplasia in Marshall Islanders exposed to nuclear fallout. JAMA 258 (1987) 629-636
39. Morimoto I., Yoshimoto Y., Sato K., et al. Serum TSH, thyroglobulin and thyroidal disorders in atomic bomb survivors exposed in youth: 30 year follow-up study. J Nucl Med 28 (1987) 1115-1122
40. Nikiforov Y., and Gnepp D.R. Pediatric thyroid cancer after the Chernobyl Disaster. Cancer 74 (1994) 748-766
41. Kazakov V.S., Demidchik E.P., and Astakhova L.N. Thyroid cancer after Chernobyl. Nature 359 (1992) 21
42. Acharya S., Sarafoglou K., La Quaglia M., et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood and adolescence. Cancer 97 (2003) 2397-2403
43. Tucker M.A., Jones P.H., Boice Jr. J.D., et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 51 (1991) 2885-2888
44. Smith M.B., Xue H., Strong L., et al. Forty year experience with second malignancies after treatment of childhood cancer: Analysis of outcome following the development of the secondary malignancy. J Pediatr Surg 28 (1993) 1342-1349
45. Neglia J.P., Friedman D.L., Yasui Y., et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 93 (2001) 618-629
46. Sigurdson A.J., Ronckers C.M., Mertens A.C., et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): A nested case-control study. Lancet 365 (2005) 2014-2023
47. Curtis R.E., Rowlings P.A., Deeg H.J., et al. Solid cancers after bone marrow transplantation. N Engl J Med 336 (1997) 897-904
48. Cohen A., Rovelli A., van Lint M.T., et al. Secondary thyroid carcinoma after allogeneic bone marrow transplantation during childhood. Bone Marrow Transplant 28 (2001) 1125-1128
49. Kyllonen L. Cancer incidence in a kidney transplanted population. Tranplant Int 13 suppl 1 (2000) S394-S398
50. Fisher D.A. Thyroid nodules in children and their management. J Pediatr 89 (1976) 866-868
51. Mazzaferri E.L. Management of a solitary thyroid nodule. N Engl J Med 328 (1993) 553-559
52. Lafferty A.R., and Batch J.A. Thyroid nodules in children and adolescence: Thirty years of experience. J Pediatr Endocrinol Metab 10 (1997) 479-486
53. McHenry C., Smith M., Lawrence A.M., et al. Nodular thyroid disease in children and adolescents: A high incidence of carcinoma. Am Surg 54 (1998) 444-447
54. Gerber M.E., Bennett E., and Maddalozzo J. Thyroid cancer in children (2007). http://Emedicine.com/ent/topic724.htm Available at: Emedicine.com/ent/topic724.htm. Accessed May 21
55. Hung W., Anderson K.D., Chandra R.S., et al. Solitary thyroid nodules in 71 children and adolescents. J Pediatr Surg 27 (1992) 1407-1409
56. Ogilivie J.B., Piatigorski E.J., and Clark O.H. Current status of fine needle aspiration for thyroid nodules. Adv Surg 40 (2006) 223-238
57. Hopwood N.J., and Kelch R.P. Thyroid masses: Approach to diagnosis and management in childhood and adolescence. Pediatr Rev 14 (1993) 481-487
58. Telander R.L., and Moir C.R. Medullary thyroid carcinoma in children. Semin Pediatr Surg 3 (1994) 188-193
59. Desjardins J.G., Khan A.H., Montupet P., et al. Management of thyroid nodules in children: a 20 year experience. J Pediatr Surg 22 (1987) 736-739
60. Yastovich A., Laberge J.M., Rodd C., et al. Cystic thyroid lesions in children. J Pediatr Surg 33 (1998) 866-870
61. Degnan B.M., McClellan D.R., and Francis G.L. An analysis of fine-needle aspiration of the thyroid in children and adolescents. J Pediatr Surg 31 (1996) 903-907
62. Cox M.R., Marshall S.G., and Spence R.A. Solitary thyroid nodule: A prospective evaluation of nuclear scanning and ultrasonography. Br J Surg 78 (1991) 90-93
63. Mazzaferri E.L., and Kloos R.T. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metabol 86 (2001) 1447-1463
64. Mazzafferi E.L., Robbins R.J., Spencer C.A., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88 (2003) 1433-1441
65. Mandel S.J., Shankar L.K., Benard F., et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 26 (2001) 6-9
66. Gerhard S.K., and Cavalieri R.R. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med 27 (2002) 1-8
67. Urhan M., Dadparvar S., Mavi A., et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging 34 (2007) 1012-1017
68. Brenner W. Is thyroid stunning a real phenomenon or just fiction?. J Nucl Med 43 (2002) 835-836
69. Robbins R.J., and Robbins A.K. Clinical review 156: Recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 88 (2003) 1933-1938
70. Ladenson P.W., Braverman L.E., Mazzaferri E.L., et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337 (1997) 888-896
71. Haugen B.R., Pacini F., Reiners C., et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84 (1999) 3877-3885
72. Iorcansky S., Herzovich V., Qualey R.R., et al. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab 90 (2005) 6553-6555
73. Hoe F.M., Charron M., and Moshang Jr. T. Use of the recombinant human TSH stimulated thyroglobulin level and diagnostic whole body scan in children with differentiated thyroid cancer. J Pediatr Endocrinol Metabol 19 (2006) 25-30
74. Schluter B., Bohuslavizki K.H., Beyer W., et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131-I scan. J Nucl Med 42 (2001) 71-76
75. 18F] Fluoro deoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234 (2001) 804-811
76. McDougall I.R., Davidson J., and Segall G.M. Positron emission tomography of the thyroid, with emphasis on thyroid cancer. Nucl Med Commun 22 (2001) 485-492
77. Shaha A.R., Byers R.M., and Terz J.J. Society of Surgical Oncology Practice Guidelines. Thyroid cancer surgical practice guidelines. Oncology 11 (1997) 1228-1232
78. Singer P.A., Cooper D.S., Daniels G.H., et al. Treatment guidelines for patients with thyroid nodules and well-differentiate thyroid cancer. American Thyroid Association. Arch Intern Med 156 (1996) 2165-2172
79. Hay I.D., Feld S., Garcia M., et al. AACE Clinical practice guidelines for the management of thyroid carcinoma. Endocr Pract 3 (1997) 60-71
80. Allen E., Owens S.E., and Waller M.L. Differentiated thyroid cancer: Lobectomy and radioiodine, a suitable treatment for all cases?. Nucl Med Commun 20 (1999) 983-989
81. Kebebew E., and Clark O.H. Differentiated thyroid cancer: "complete" rational approach. World J Surg 24 (2000) 942-951
82. Newman K.D., Black T., Heller G., et al. Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: A report from the Surgical Discipline Committee of the Children's Cancer Group. Ann Surg 227 (1998) 533-541
83. Bingol-Kologlu M., Tanyel F.C., Senocak M.E., et al. Surgical treatment of differentiated thyroid cancer in children. Eur J Pediatr Surg 10 (2000) 347-352
84. Welch Dinauer C.A., Tuttle R.M., Robie D.K., et al. Extensive surgery improves recurrence-free survival for children and young patients with class I papillary thyroid carcinoma. J Pediatr Surg 34 (1999) 1799-1804
85. Jarzab B., Handkiewicz Junak D., Wloch J., et al. Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur J Nucl Med 27 (2000) 833-841
86. Haveman J.W., van Tol K.M., Rouwe C.W., et al. Surgical experience in children with differentiated thyroid carcinoma. Ann Surg Oncol 10 (2003) 15-20
87. Hallwirth U., Flores J., Kaserer K., et al. Differentiated thyroid cancer in children and adolescents: The importance of adequate surgery and review of the literature. Eur J Pediatr Surg 9 (1999) 359-363
88. La Quaglia M.P., Black T., Holcomb G.W., et al. Differentiated thyroid cancer: Clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group. J Pediatr Surg 35 (2000) 955-960
89. Hung W., and Sarlis N. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 12 (2002) 683-702
90. Seidlin S.M., Marinelli L.D., and Oshry E. Radioactive iodine therapy, effect of functioning metastases of adenocarcinoma of the thyroid. JAMA 132 (1946) 838-847
91. Schlumberger M., Tumbiana M., DeVathaire F., et al. Long-term treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63 (1986) 960
92. DeGroot L.J., Kaplan E.L., McCormick M., et al. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71 (1990) 414-424
93. Mazzaferri E.L., and Jhiang S.M. Long-term impact of initial surgery and medical therapy on papillary and follicular thyroid cancer. Am J Med 97 (1994) 418-428
94. 131I therapy of thyroid cancer patients. QJ Nucl Med 43 (1999) 324-335
95. Pacini F., Ladenson P.W., Schlumberger M., et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91 (2006) 926-932
96. 131I therapy for pediatric thyroid cancer. Semin Pediatr Surg 6 (1997) 128-133
97. Mazzaferri E.L. Long-term outcome of patients with differentiated thyroid carcinoma: Effect of therapy. Endocr Pract 6 (2000) 469-476
98. Degroot L.J., and Reilly M. Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 96 (1982) 51-53
99. Maxon H.R., Thomas S.R., Hertzberg V.S., et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309 (1983) 937-941
100. Maxon H.R. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 43 (1999) 313-323
101. Catz B., Petit D., and Starr P. The diagnostic and therapeutic value of thyrotropic hormone and heavy dosage scintigram for the demonstration of thyroid cancer metastases. Am J Med Sci 237 (1959) 158-164
102. Nemec J., Rohling S., Zamrazil V., et al. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 20 (1979) 92-97
103. Waxman A., Ramanna L., Chapman L., et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation. J Nucl Med 22 (1981) 861-865
104. Mazzaferri E.L. Empirically treating high serum thyroglobulin levels. J Nucl Med 46 (2005) 1079-1088
105. 131I wholebody scanning results?. J Nucl Med 46 (2005) 1164-1170
106. Luster M., Lippi F., Jarzab B., et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12 (2005) 49-64
107. Handscheid H., Lassmann M., Luster M., et al. Iodine kinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47 (2006) 648-654
108. Robbins R.J., Dreidger A., and Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16 (2006) 1121-1130
109. Lau W.F., Zacharin M.R., Waters K., et al. Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy. Intern Med J 36 (2006) 564-570
110. Edmonds C.J., and Smith T. The long term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 59 (1986) 45-51
111. van Nostrand D., Neutze J., and Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 27 (1986) 1519-1527
112. Maxon H., Thomas S., and Samaratunga R. Dosimetric considerations in radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 7 (1987) 183-187
113. Vini L., Al-Saadi A., Pratt B., et al. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 78 (2002) 92-93
114. Raymond J.P., Izembart M., Marliac V., et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocr Metab 69 (1989) 186-189
115. Pacini F., Gasperi M., Fugazzola L., et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 35 (1994) 1418-1422
116. Dottorini M.E. Genetic risk assessment after I-131 exposure: An opportunity and obligation for nuclear medicine. J Nucl Med 37 (1996) 612-614
117. Sarkar S.D., Beierwaltes W.H., Gill S.P., et al. Subsequent fertility and birth histories of children and adolescents treated with I-131 for thyroid cancer. J Nucl Med 17 (1976) 460-464
118. Smith M.B., Xue H., Takahashi H., et al. Iodine-131 thyroid ablation in female children and adolescents: long-term risk of infertility and birth defects. Ann Surg Oncol 1 (1994) 128-131
119. Schlumberger M., De Vathaire F., Ceccarelli C., et al. Outcome of pregnancy in women with thyroid carcinoma. J Endocrinol Invest 18 (1995) 150-151
120. Schlumberger M., De Vathaire F., Ceccarelli C., et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37 (1996) 606-612
121. Ceccarelli C., Bencivelli W., Morciano D., et al. 131-I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: Results of a retrospective study. J Clin Endocrinol Metab 86 (2001) 3512-3515
122. Balan K.K., and Critchley M. Outcome of pregnancy following treatment of well differentiated thyroid cancer with 131-iodine. Br J Obstet Gynaecol 99 (1992) 1021-1022
123. Casara D., Rubello D., Saladini G., et al. Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: Potential risks and recommendations. Eur J Nucl Med 20 (1993) 192-194
124. Dottorini M.E., Lomuscio G., Mazzucchelli L., et al. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 36 (1995) 21-27
125. Lin J.D., Wang H.S., Weng H.F., et al. Outcome of pregnancy after radioiodine treatment for well differentiated thyroid carcinomas. J Endocrinol Invest 21 (1998) 662-667
126. Ayala C., Navarro E., Rodriguez J.R., et al. Conception after I-131 therapy for differentiated thyroid cancer. Thyroid 8 (1998) 1009-1011
127. Handelsman D.J., Conway A.J., Donnelly P.E., et al. Azoospermia after iodine-131 treatment for thyroid carcinoma. Br M J 281 (1980) 1527
128. Handelsman D.J., and Turtle J.R. Testicular damage after radioiodine (I-131) therapy for thyroid cancer. Clin Endocrinol 18 (1983) 465-472
129. Ahmed S.R., and Shalet S.M. Gonadal damage due to radioactive iodine (I-131) treatment for thyroid carcinoma. Postgrad Med J (1984)
130. Gutierrez S., Carbonell E., Galofre P., et al. Cytogenic damage after I-131 treatment for hyperthyroidism and thyroid cancer: A study using the micronucleus test. European J Nucl Med 26 12 (1999) 1589-1596
131. Hagmar L., Brogger A., Hansteen I.-L., et al. Cancer risk in humans predicted by increased levels of chromosome aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 54 (1994) 2919-2922
132. Bonassi S., Abbondandolo A., Camurri L., et al. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans?. Preliminary results of an Italian cohort study. Cancer Genet Cytogenet 79 (1995) 133-135
133. Brinker H., Hansen H.S., and Anderson A.P. Induction of leukemia by 131-I treatment of thyroid cancer. Br J Cancer 28 (1973) 232-237
134. Holm L.E., Dahlqvist I., Eng S.M., et al. Malignant thyroid tumors after Iodine-131 therapy. N Engl J Med 303 (1980) 188-191
135. Hoffmann D.A., McConahey W.M., Fraumeni J.F., et al. Cancer incidence following treatment of hyperthyroidism. Int J Epidemiol 11 (1982) 218-224
136. Hall P., Holm L.E., Lundell G., et al. Cancer risks in thyroid cancer patients. Br J Cancer 64 (1991) 159-163
137. Hall P., Boice Jr. J.D., Berg G., et al. Leukaemia incidence after iodine-131 exposure. Lancet 340 (1992) 1-4
138. Shimon I., Kneller A., and Olchovosky D. Chronic myeloid leukaemia following 131-I treatment for thyroid carcinoma: A report of two cases and a review of the literature. Clin Endocrinol 43 (1995) 651-654
139. Laurenti L., Salutari P., Sica S., et al. Acute myeloid leukemia after iodine-131 treatment for thyroid disorders. Ann Hematol 6 (1998) 271-272
140. Green D.M., Edge S.B., Penetrante R.B., et al. In situ breast carcinoma after treatment during adolescence for thyroid cancer with radioiodine. Med Pediatr Oncol 24 (1995) 82-86
141. Rubino C., De Vathaire R.C., Dottorini M.E., et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 89 (2003) 1638-1644
142. Kloos R.T., and Mazzaferri E.L. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90 (2005) 5047-5057
143. Mazzaferri E.L., and Kloos R.T. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?. J Clin Endocrinol Metab 87 (2002) 1490-1498
144. Durski J.M., Weigel R.J., and McDougall I.R. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Nucl Med Commun 21 (2000) 521-528
145. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84 (1999) 2291-2302
146. Grunwald F., Kalicke T., Feine U., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of amulticentre study. Eur J Nucl Med 26 (1999) 1547-1552
147. 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 86 (2001) 3779-3786